An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.
about
Remodeling of the Host Cell Plasma Membrane by HIV-1 Nef and Vpu: A Strategy to Ensure Viral Fitness and PersistenceConformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesAntigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challengeStructural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 InfectionDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingVaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesImmune-correlates analysis of an HIV-1 vaccine efficacy trialSurvivors Remorse: antibody-mediated protection against HIV-1.Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea PigsFc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.HIV prevention transformed: the new prevention research agendaIdentification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.Lessons learned from human HIV vaccine trials.HIV-1 vaccines: challenges and new perspectivesHumoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionNovel directions in HIV-1 vaccines revealed from clinical trialsAdvancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.Epitope target structures of Fc-mediated effector function during HIV-1 acquisition.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesVaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrumPlasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individualsSlaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cellsBalance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Activation of NK cells by ADCC antibodies and HIV disease progression.Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmissionIdentification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
P2860
Q26767362-8250D1E0-202E-482C-8BE4-71721A3FB6A5Q26782237-EF78B7AD-710E-45AD-93D3-A4D17709B560Q27318508-4D8B4E2A-B5FE-4D01-B145-7EAE53C32DFCQ27320687-E0026FEC-21D9-4D64-B962-0C5DA53CD647Q27342615-8C70C6E6-ECB4-4C2C-B041-04D1EB36C7B3Q27640572-07BC9752-B035-470F-900B-53FEECA5781CQ27675486-F4903CCB-DB3A-459B-AA80-895C74EF3DD0Q27675879-26F7F178-04BA-4C53-85E0-F2CD5ECD62B1Q27687375-6E815311-F549-486A-97D4-B40A95EF3C86Q28299280-615AB850-9E50-4838-978D-77595B9418C4Q29617377-4DF8F529-D5D0-4D54-B9D7-68E80724E840Q30238730-7BB25C04-5F78-442C-9E7F-DCEFE8A1CE19Q30278897-FAA35D41-2AE1-4E61-8247-D28AB70D4C92Q30400230-5BA122E0-76C7-46B4-825D-9E51AAD913FDQ30404963-1A8C60D9-7EB3-4ED2-BE35-3FADD7481CE8Q30428189-A6D80081-C70E-4096-AE57-BA38F7A29C2DQ33557844-398DBA89-2A79-47C1-AC86-D0CC6A8341C2Q33577972-052E3C83-F087-4FA1-AF38-C8FC37936D03Q33620546-1B5B4EDA-BE0E-434A-9259-A1740A38847CQ33645528-A11251CE-745F-4631-B83D-FB5CF83E184DQ33742529-EA4DFD30-EB23-412D-88C7-7A74CAA2F015Q33804531-23FE9204-C49C-4A3D-B97D-B7D478364486Q33900395-98C7C5BA-5E84-4399-BD6F-50ED9C64EB20Q33924272-81374C4D-9A7F-4EBF-B242-EC752F6BD11FQ34057711-247658A3-DDB2-4214-8749-395AF0FB50FFQ34059103-309FA58B-5279-4F19-BC57-8BF1B2C08271Q34125277-DC421C7A-0E7D-456A-80AD-BC077D399E2EQ34280115-57F72B04-A9D3-45BD-8157-6FCAF9C1D849Q34374835-9B6AEDD6-7CF5-4080-81CB-37C4783D456CQ34402446-FB2C90C9-474F-46ED-9D8A-2D065465EA15Q34869927-F0D64B98-C40E-42BB-9FB6-F4C2F31881A0Q34885869-9CB97D88-CF3E-47FC-A1AA-0477AD2B7A71Q34992575-A04CF60F-3A21-4E67-A01F-A3A908D344CAQ34992670-039073F1-9AA9-4088-8D9C-04FC0C28052DQ35156935-5EA5C087-C2AD-4ED3-B1DA-9A31DB076291Q35218850-9EA3F75A-50FB-4D2C-BF9D-9930B01C0361Q35488153-BAC74953-4C50-4490-963C-76EC40ABB55FQ35600028-DC7ACA74-EE14-4E03-830A-32C5C7003C98Q35641144-133B1318-FE98-43D1-BA3C-F589F7297E04Q35729899-811FA8B0-F06B-46DB-A563-7E639127C3DC
P2860
An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An HIV-1 gp120 envelope human ...... epitope in human HIV-1 serum.
@ast
An HIV-1 gp120 envelope human ...... epitope in human HIV-1 serum.
@en
type
label
An HIV-1 gp120 envelope human ...... epitope in human HIV-1 serum.
@ast
An HIV-1 gp120 envelope human ...... epitope in human HIV-1 serum.
@en
prefLabel
An HIV-1 gp120 envelope human ...... epitope in human HIV-1 serum.
@ast
An HIV-1 gp120 envelope human ...... epitope in human HIV-1 serum.
@en
P2093
P2860
P50
P356
P1433
P1476
An HIV-1 gp120 envelope human ...... epitope in human HIV-1 serum.
@en
P2093
Christina Ochsenbauer
Daniel Kozink
Georgia D Tomaras
James A Hoxie
James E Robinson
John C Kappes
Justin Pollara
M Anthony Moody
Mark Drinker
S Munir Alam
P2860
P304
P356
10.1128/JVI.00171-11
P407
P577
2011-05-04T00:00:00Z